Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adjuvant Vaccines Could Have Helped To Prevent H1N1 Shortfall, Industry Tells Congress

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has yet to approve adjuvanted influenza vaccines when they have been in use in Europe since 1997.
Advertisement

Related Content

Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Adjuvanted Flu Vaccines Get Booster: House Report Presses FDA On Approval
Adjuvanted Flu Vaccines Get Booster: House Report Presses FDA On Approval
FDA, EMA Confidentiality Agreement Expanding Into "Clusters"
FDA, EMA Confidentiality Agreement Expanding Into "Clusters"
First Cell-Derived Flu Vaccine Reaches Advisory Committee
First Cell-Derived Flu Vaccine Reaches Advisory Committee
H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say
H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say

Topics

Advertisement
UsernamePublicRestriction

Register

PS068763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel